In 1950s, double-stranded deoxyribonucleic acid (DNA) 
Introduction
In 1865, Gregor Mendel established a quantitative analysis of breeding experiments between various pea strains and provided a statistical basis of his laws of inheritance. A Danish botanist, Johannsen, subsequently coined the term 'gene' for the hereditary factors, i.e. units of heridity. Since then the sciences of 'Genetics' and 'Medical Genetics, have evolved and DNA has been identi ed as the biochemical basis of heredity. l,2 A gene, segment of DNA consisting of regulatory and structural parts, is responsible for the production of a particular polypeptide/protein. All genes on all chromosomes together, a genome, constitute the information a person inherits from his or her parents' information that sets limits on body structure, function and behavior. l, 2 In humans, a copy of the entire genome -more than 3 billion base pairs -is contained in all cells that have a nucleus. 3 A permanent change in DNA that has pathological consequence is known as mutation, which may be spontaneous or induced and classi ed as genomic mutation, chromosomal mutation and sub-microscopic gene (point) mutation that involves vast majority of hereditary diseases. Accordingly, genetic disorders are categorized as single gene disorders, chromosomal disorders, somatic cell gene disorders, mitochondrial gene mutations and multifactorial genetic disorders. (Table-I ) Can medical treatment leading to permanent genetic cure or at least long term therapeutic bene t or remission possible for these disorders? e answer is probably 'yes' as the initial thought of 'Gene erapy' have been transformed recently into reality because of intense medical research e orts. In the mid-1980s, the focus of gene therapy was entirely on treating diseases caused by such single gene defects as hemophilia, Duchenne's muscular dystrophy and sickle cell anemia. In the late 1980s and early 1990s, the concept of gene therapy was expanded into a number of acquired diseases. When human testing of rst-generation vectors began in 1990, scientists learned that the vactors didn't transfer genes e ciently and that they were not su ciently weakened. Expression and use of the therapeutic genes did not last very long. In 1995, a public debate led to the consensus that gene therapy has value although many unanswered questions require continued basic research. As the eld has matured over the last decades, it has drawn the attention of biopharmaceutical industry, which has begun to sort out its own role in gene therapy. is is critical because ultimately this industry will bring gene theraphies to large patient populations. e remarkable progress has been achieved in the eld of gene therapy over the last 15 years or so. 4 Gene therapy is the application of various technologies including recombinant DNA technology for the introduction of a relevant functional gene, i.e. exogenous DNA or genetic material, into a cell to achieve therapeutic e ects for heriditary and acquired human genetic disorders. 5, 6 In the present review article an attempt has been made to give an updated account of the present status of gene therapy for primary immunode ciency diseases in human Gene therapy for primary immunode ciency diseases: where are we now?
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•
A substantial disease burden and a favorable risk-bene t ratio in comparison with alternative therapy.
• Su cient knowledge of the molecular basis of the disease to be con dent that the gene transfer is likely to ameliorate or correct the biochemical pathology and to prevent or reverse critical phenotypic abnormalities.
Whereas loss of functional mutations will require replacement with a functional gene, some dominant alleles, such as dominant negative alleles, will require inactivation of the mutant gene or its product.
• Appropriate regulatory components for the transferred gene, tight regulation of the level of gene expression is relatively important in some disease and critical in others. In thalassemia, for example, over-expression of the transferred gene would cause a new imbalance of globin chains, whereas low levels of expression would be ine ective. In contrast, in some enzymopathies, abnormally high levels of expression may have no adverse e ect.
• An appropriate target cell with ideally, a long half-life or good replicative potential in vivo.
• Adequate data from cultured cell and animal studies to indicate that the vector, gene construct, and target cell are both e cacious and safe.
• Protocol review and approval by an institutional Review Board and in most countries an oversight governmental agency.
Types of gene therapy
To deliver genes to speci c tissues and correct genetic disorders two general approaches and strategies are used, i.e. Ex-vivo approach: e target cells are removed from the body and a normal gene is then introduced in vitro by one of the gene delivery methods; In vivo approach (Direct gene transfer): e therapetrtic gene is introduced into the a ected tissues without removing cells from the body. 6, [11] [12] [13] Type of gene therapy are-Somatic cell therapy: e A. Single gene defects 
E. Mitochondrial mutations
Identi cation of mitochondrion has been a tremendous achievement of accomplished scientists who tried to understand the essence of life. We now know that the mitochondrion is the intracellular powerhouse that generates ATP, the chemical energy source, though a chain of reactions called oxidative phosphorylation, Now, the mitochondrion genes are known to play a major role in many important health problems of the 21 st centry including Alzhimer's disease, diabetes mellitus, senescence, autism, carcinogenesis, encephalopathies. [7] [8] [9] [10] 
Ideal criteria, approaches and types of gene therapy
Minimal requirements of gene therapy of a genetic disorder are the following . 6, [11] [12] [13] • Identi cation of the a ected locus or at least of the biochemical basis of the disorder.
• 
Gene therapy for primary immunode ciency diseases
Since the demonstration that genes could be successfully transferred into humans in 1990, gene therapy has made much progress. It has become established as an alternative strategy to bone marrow transplantation (BMT) in carefully selected individuals.
One of the primary immunode ciency diseases (PIDs), adenosine deaminase (ADA) de ciency form of severe combined immunode ciency (SClD), meets the criteria for successful gene therapy. ADA de ciency is the rst human disease in which somatic gene therapy was attempted. Building on promising results in SCID due to ADA de ciency, gene therapy has recently been extended to X-linked SCID associated with mutations in the common γ-chain cytokine receptor using a retroviral vector (Figure-2 ). 16
Figure-1: Gene therapy for adenosine deaminase (ADA) de ciency

Figure-2: Gene therapy for severe combined immunode ciency
Several children with this form of SCID are currently in remission with durable restitution to date of T and B cell fuction. 15, 16 Recipients, however, face the risk of vector-induced in ammation (as seen with adenoviral vectors), overwhelming viral infection by the vector and the possibility, with retroviral vectors, of insertional mutagnesis, i.e. induction of new mutations in the host cell genome by the retrovirus. Delight at the apparent success of gene therapy has recently been dampened by the development, of T-cell leukemia several years after engraftment due to insertional mutagnesis, a ecting the LMO2 oncogene, a possibility that had been feared. New vectors may help to outcome this potential limitations in the near future. 15, 16 Recently, it has been reported that 60 patients a ected by SCID due to IL2R gene (IL2RG PIDs have played a major role in the development of gene therapy for monogenic diseases of the bone marrow. e last decade has seen convincing evidence of long-term disease correction as a result of ex-vivo viral vector-mediated gene transfer into autologous haematopoietic stem cells. e success of these early studies has been balanced by the development of vector-related insertion mutagenic events. More recently the use of alternative vector designs with self-inactivating designs, which have an improved safety pro le. 19 e ongoing development of safer vector platforms and gene-correction technologies together with improvements in cell-transduction techniques and optimized conditioning regimes is likely to make gene therapy amenable for a greater number of PlDs. lf long-term e cacy and safety are shown, gene therapy will become a standard treatment option for speci c form of PIDs. We eagerly wait until the results of ongoing clinical studies, the experiences and perspectives of gene therapy for SCID-X1 and ADS-SCID, WAS, CGD & IPEX in comparison to allogenic transplantation are know. Recent developments in gene therapy for other human diseases, such as cancers and autoimmunity are considerable which are our next target to review in the near future.
